Skip to main content

Restriction of HIV and coronavirus infections by the innate immunity protein Shiftless

Project description

Molecular inhibition of viral infectivity

Viruses must hijack cellular machinery to survive, replicate and spread. To maximise the information content of their genomes, viruses have adopted the mechanism of programmed ribosomal frameshifting, which allows parallel translation of multiple protein copies from the same mRNA molecule. The EU-funded RIBOSFL project focuses on the restriction factor Shiftless (SFL), which is known to block virus infectivity by inhibiting ribosomal frameshifting. Researchers aim to study the mechanism of action of SFL, which will pave the way for the design of new antiviral therapeutics. This is of great clinical significance for key pathogens such as HIV and SARS-CoV-2.

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Net EU contribution
€ 174 806,40
Address
Hofgartenstrasse 8
80539 Munchen
Germany
Activity type
Research Organisations
Non-EU contribution
€ 0,00